Effects of Left Atrial Appendage Resection and Marshall Ligament Amputation on Clinical Outcome in Patients Undergoing Off-pump Coronary Artery Bypass
Launched by CHINA NATIONAL CENTER FOR CARDIOVASCULAR DISEASES · Jan 5, 2020
Trial Information
Current as of August 19, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring the effects of two surgical techniques—removing a small pouch in the heart called the left atrial appendage and cutting a band of tissue known as the Marshall ligament—during a heart surgery called off-pump coronary artery bypass. The goal is to see if these procedures can help lower the chances of patients developing new atrial fibrillation (a common heart rhythm problem) and having a stroke after their surgery. Atrial fibrillation can increase the risk of stroke and other complications, so understanding the benefits of these techniques is important.
To be part of this study, participants need to be undergoing their first isolated off-pump coronary artery bypass surgery and must not have had any previous heart surgeries or current issues with atrial fibrillation. The trial is currently recruiting patients between the ages of 65 and 74. If eligible, participants can expect to undergo the surgery with these additional procedures and will be monitored for their heart health and any complications following the surgery. This research will help doctors better understand the potential benefits of these techniques in improving patient outcomes after heart surgery.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • isolated first off-pump coronary artery bypass
- Exclusion Criteria:
- • Preoperative atrial fibrillation or a history of atrial fibrillation;
- • Concurrent cardiac or non-cardiac surgery
- • Intraoperative convert to bypass bypass surgery
- • Emergency surgery
- • History of previous cardiac surgery
- • Severe organ dysfunction
About China National Center For Cardiovascular Diseases
The China National Center for Cardiovascular Diseases (NCCD) is a leading research and clinical trial sponsor dedicated to advancing cardiovascular health in China and globally. As a prominent institution, NCCD focuses on innovative research, clinical management, and education in cardiovascular medicine. The center plays a crucial role in conducting rigorous clinical trials aimed at developing new therapies and improving patient outcomes for cardiovascular diseases. Through collaboration with national and international partners, NCCD is committed to enhancing the understanding of cardiovascular conditions and translating research findings into practical applications for improved healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, , China
Patients applied
Trial Officials
Hansong Sun, doctor
Principal Investigator
Chinese Academy of Medical Sciences, Fuwai Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials